Statements (61)
| Predicate | Object |
|---|---|
| gptkbp:instance_of |
gptkb:healthcare_organization
|
| gptkbp:bfsLayer |
5
|
| gptkbp:bfsParent |
gptkb:nivolumab
gptkb:Keytruda |
| gptkbp:affects |
heart problems
secondary cancers fertility issues lymphatic system lung issues |
| gptkbp:age |
15 to 30 years
over 55 years |
| gptkbp:associated_with |
gptkb:Epstein-Barr_virus
|
| gptkbp:clinical_trial |
ongoing research
|
| gptkbp:end_of_life |
5-year survival rate
|
| gptkbp:events |
regular check-ups
monitoring for recurrence |
| gptkbp:first_described_by |
gptkb:Thomas_Hodgkin
|
| gptkbp:genetic_diversity |
chromosomal abnormalities
|
| https://www.w3.org/2000/01/rdf-schema#label |
classical Hodgkin lymphoma
|
| gptkbp:is_a |
gptkb:healthcare_organization
|
| gptkbp:is_involved_in |
patient support organizations
|
| gptkbp:is_vulnerable_to |
gptkb:healthcare_organization
|
| gptkbp:number_of_stages |
stage I
stage IV stage II stage III |
| gptkbp:public_awareness |
September
|
| gptkbp:research_focus |
genetic markers
immunotherapy advancements treatment personalization |
| gptkbp:risk_factor |
age
family history gender |
| gptkbp:side_effect |
nausea
hair loss increased risk of infection |
| gptkbp:social_responsibility |
CT scan
generally good biopsy imaging tests PET scan |
| gptkbp:symptoms |
fatigue
weight loss fever night sweats swollen lymph nodes itchy skin pain in lymph nodes |
| gptkbp:treatment |
gptkb:vaccine
radiation therapy chemotherapy targeted therapy stem cell transplant ABVD BEACOPP complete remission partial remission |
| gptkbp:type_of |
lymphocyte-depleted
lymphocyte-rich mixed cellularity nodular sclerosis |